Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Oct 03, 2018 3:55pm

139 Views

Post# 28740117

RE:RE:ANOTHER 150,000 insider buy...Whatever is coming will be big

Mikchicken wrote: As much as I'm enjoying these insider buys because I'm sure its a good thing, I'm also looking forward to the end of the insider buying for a while too. My reasoning is because like the rest of you I'm waiting to hear some news. I'm sure there will need to be some kind of a blackout period before any significant news is released so seeing as we had another insider buy yesterday im sure any news is still a week or two away. Just my thoughts.

Depends what news you're waiting for. Some things, like the clinical trials, have already been well signalled. Updates on start of those would seem fine. What else you waiting for?

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity